glp 1 gip agonist Targeting GLP-1, & GCG in Obesity and Type 2 Diabetes Research GLP1 agonists: current and future

First-time prescribing of AOMs also decreased in September 2025, relative to June 2025 (-9.5%)

This approach stays intentionally low, aiming for a personalized balance between results and tolerability

Tirzepatide Introduced in 2022 under the brand name Mounjaro, Tirzepatide is a medication that combines the effects of GIP (Glucose-Dependent Insulinotropic Polypeptide) and GLP-1 receptor agonists

Wegovy (semaglutide) tablets, for oral use

(2021) 4:e2127573

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU) Diabet Med